At this moment, specific therapies for the treatment of HSMR syndrome due to pathogenic mutations in CNNM2 have yet to be developed. At this moment, the main advices are:

  • Mg2+ supplementation
  • Anti-consulvants, in case of persistent refractory epilepsy
  • Speech therapy in case of speech/communication delay
  • Physiotherapy if motor skills defects are identified